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The aim of this study was to evaluate whether the HER2 expression in breast cancer is retained in metastases. The HER2 expression
in primary tumours and the corresponding lymph node metastases were evaluated in parallel samples from 47 patients. The
HercepTest was used for immunohistochemical analyses of HER2 overexpression in all cases. CISH/FISH was used for analysis of
gene amplification in some cases. HER2 overexpression (HER2-scores 2þ or 3þ) was found in 55% of both the primary tumours
and of the lymph node metastases. There were only small changes in the HER2-scores; six from 1þ to 0 and one from 3þ to 2þ
when the metastases were compared to the corresponding primary tumours. However, there were no cases with drastic changes in
HER2 expression between the primary tumours and the corresponding lymph node metastases. The literature was reviewed for
similar investigations, and it is concluded that breast cancer lymph node metastases generally overexpress HER2 to the same extent
as the corresponding primary tumours. This also seems to be the case when distant metastases are considered. It has been noted that
not all patients with HER2 overexpression respond to HER2-targeted Trastuzumab treatment. The stability in HER2 expression is
encouraging for efforts to develop complementary forms of therapy, for example, therapy with radionuclide-labelled Trastuzumab.
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There is a need for new therapy modalities to improve the survival
time for patients with disseminated breast cancer. One approach is
to target the antibody Trastuzumab (Herceptint) to the HER2
receptor when it is overexpressed (Pegram et al, 2000; McKeage
and Perry, 2002). HER2 (also called ErbB2 or neu) is a
transmembrane receptor in the epidermal growth factor (EGF)
receptor family. HER2 has no known natural ligand and instead
seems to be activated via dimerisation with other receptors in the
family: EGFR, HER3 or HER4 (Yarden and Sliwkowski, 2001).
HER2 is overexpressed in 25–30% of all breast cancers (Cobleigh
et al, 1999; Andersson et al, 2002) and probably in a higher
percentage in the more malignant subgroup that form lymph node
or distant metastases (Xu et al, 2002; Eccles, 2002; Esteva et al,
2002, see also the results in this study).
Binding of Trastuzumab to HER2 blocks growth-stimulating
intracellular signalling, decreases the cellular repair capacity after
chemo- and radiotherapy, and possibly also improves the
apoptosis capacity (Pegram et al, 2000; McKeage and Perry,
2002). Thus, the antibody is expected to impart therapeutical
effects either alone (Cobleigh et al, 1999) or in combination with
chemotherapy where taxan seems especially promising (Slamon
et al, 2001).
However, it has been shown that less than half of the patients
with a high expression of HER2 respond to Trastuzumab treatment
whether the antibody is given alone or in combination with
chemotherapy (Cobleigh et al, 1999; Slamon et al, 2001; McKeage
and Perry, 2002). The reason for resistance to Trastuzumab among
tumours that overexpress HER2 is not well clarified, although an
increased signalling via the IGF-I receptor has been associated with
lack of Trastuzumab response (Lu et al, 2001, 2004). Another
obvious explanation might be heterogeneity in the expression of
HER2 between primary and metastatic tumour cells. It is, for
example, feared that the overexpression of HER2 may sometimes
be lost in metastases (Thor, 2001). The aim of the present study
was to further add to the body of data on this subject and to review
some recently published studies.
MATERIALS AND METHODS
Patients
Tissue sections were obtained from the Scandinavian Breast
Cancer Group study, SBG 9404 (Sjo ¨stro ¨m et al, 2002). All patients
with samples from both the primary tumour and from a lymph
node metastasis were included. An inclusion criterion for the SBG
9404 study was also the presence of distant metastases. However,
tissue samples were not taken from the distant metastases so that
these were not available for HER2 analysis. Samples with less good
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yhistological quality were excluded if the corresponding FISH
analysis was also verified as being of bad quality (see below). High-
quality material of both primary tumours and the corresponding
metastases were thereafter obtained from 47 patients. All the
samples were coded and the analyses were carried out without
knowing as to which samples formed pairs of primary tumour and
metastasis. The code was then broken and all data were
summarised. The patient and tumour characteristics of the 47
analysed patients are shown in Table 1.
HER2-staining
The histological and immunohistochemical staining was carried
out as previously described (Sjo ¨stro ¨m et al, 2002). Briefly, the
tissues were fixed in 4% buffered formalin, processed and
embedded in paraffin. Sections, 4-mm thick, were then cut and
dried for 12h at 371C. The sections were deparaffinised in xylene
and rehydrated through graded concentrations of ethanol to
distilled water. Incubating the sections in methanol and hydrogen
peroxide for 30min quenched endogenous peroxidase. Immuno-
histochemical stainings were performed by using the Elite ABC Kit
(Vectastain, Vector Laboratories, Burlingame, CA, USA). Blocking
serum was applied for 15min and followed by incubation with
rabbit anti-human c-erbB-2 oncoprotein (Dako, Glostrup, Den-
mark) diluted 1:500. Sections were then incubated with the
biotinylated secondary antibody and were visualised using the
peroxidase substrate 3-amino-9-ethyl-carbazole (AEC) (Sigma A-
5754) as chromogen. Finally, the sections were counterstained with
Mayer’s haematoxylin and mounted with Aquamount (BDH Ltd,
Poole, UK).
HER2-scores
The HER2 expression was scored using the HercepTest criteria.
The HER2-score was based on a 0 to 3þ scale. 0 corresponded to
tumour cells that were completely negative, 1þ corresponded to
faint perceptible staining of the tumour cell membranes, 2þ
corresponded to moderate staining of the entire tumour cell
membranes and 3þ indicated strong circumferential staining of
the entire tumour cell membranes creating a fishnet pattern. The
Canadian and the DAKO HercepTest guidelines (Bilous et al, 2003)
that require more than 10% of the tumour cells to be stained were
applied. Owing to the discussions about relevant cutoff levels
(Bilous et al, 2003), we also considered other levels within the
range 10–40%. Cytoplasmic staining was considered nonspecific
and was not included in the scoring. As positive controls, we used
in-house positive control tissue sections as well as positive control
sections supplied by DAKO. In addition, we applied sections from
pellets made from the strongly HER2-positive SK-BR-3 breast
cancer cells (Bilous et al, 2003) that were stained in the same
manner. As negative controls, we used HER2-positive breast
cancer tissue but excluded the primary antibody. We also used
normal tissues that are expected not to express HER2 such as
normal tissues near the primary tumours (normal breast glands
and connective tissue seen in the same sections as the tumour
cells) as internal negative controls. In the metastases sections, we
used lymphocytes and the surrounding capsule of the lymph nodes
as negative internal controls.
FISH and CISH
FISH and CISH analyses of HER2 (erbB2) gene amplification were
carried out to validate the immunohistochemistry. This verified
that the primary tumours with high HercepTest scores (2þ or
3þ) were also gene amplified. For a few cases, methodological
comparison was also made between FISH and CISH, and an exact
match was found. Samples that showed erbB2 gene amplification
with FISH also showed amplification with CISH while samples,
which did not show amplification with FISH, did not show
amplification with CISH.
For the FISH assay, we applied the PathVysion HER-2 DNA
Probe Kit (Vysis Inc., Downers Grove, IL, USA). Briefly, formalin-
fixed paraffin-embedded tissue specimens were placed on slides.
The DNA was denaturated and allowed to hybridise with two
fluorescent probes. The chromosome 17-marker probe gave green
fluorescence and the erbB2 marker probe gave intense orange
fluorescence. The cell nuclei were stained with DAPI giving blue
fluorescence. The three fluorescence signals were observed
sequentially in the same field of view using a microscope, Leica
DMLB, equipped with appropriate filters. The scoring conditions
followed the recommendations given by Vysis Inc. Gene amplifica-
tion was at hand when the number of orange spots per cell was
significantly higher than the number of green dots per cell.
The CISH analysis was carried out according to the description
by Rummukainen et al (2001). Briefly, before hybridisation, the
tissue sections were deparaffinised, washed and dried. They were
then incubated in buffer at a high temperature in an autoclave and
after cooling and rinsing the sections were treated with pepsin,
washed, dehydrated and dried. A digoxigenein-labelled HER2
probe was added and the slides were sealed and denaturated, and
hybridisation was allowed to take place. The slides were then
opened, washed and the HER2 probe was finally detected using
antidigoxigenin, goat anti-mouse HRP and DAB. The slides were
incubated with DAB enhancer, counterstained with haematoxylin
and then analysed in a light microscope.
Excluded cases
In six patients, the primary tumours and the lymph node
metastases deviated severely with respect to their HercepTest
score. In all six cases, the samples with lowered HercepTest scores
(five metastases and one primary tumour) also had a distorted
histological and morphological appearance. In addition, FISH
analyses revealed that the samples with lowered HercepTest scores
were of such poor quality that the chromosome 17 marker could
not be identified. Further, the DAPI stainings were blurry and did
not stain the nuclei as expected. We were unable to obtain more
Table 1 Tumour and patient characteristics (n¼47)
Characteristics Patients, n (%)
Histology
Ductal 44 (94)
Lobular 3 (6)
Medullary 0 (0)
Histological grade
Grade I 5 (11)
Grade II 30 (64)
Grade III 12 (25)
T-stage
pT1 10 (21)
pT2 25 (53)
pT3 11 (23)
pT4 1 (2)
Oestrogen receptor status
Positive 23 (49)
Negative 23 (49)
Unknown 1 (2)
Median age (years) 52.2
Menopausal status
Premenopausal 3 (6)
Postmenopausal 44 (94)
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ymaterial from these patients and they were therefore excluded
from the analysis. In the remaining analysed cases (n¼47), the
quality of both the primary tumour and the metastases samples
was high.
RESULTS
The HER2-scores for the analysed 47 primary tumours and the
corresponding 47 lymph node metastases are shown in Table 2.
There were no changes between the primary tumours and the
corresponding lymph node metastases in the majority of cases.
Only seven changes were observed. There were six changes from
1þ to 0 and one change from 3þ to 2þ when the metastases
were compared to the primary tumours. Only samples scored as
2þ or 3þ were gene amplified as seen from analyses with both
FISH and CISH.
The 10% cutoff level was applied. This means that only samples
with more than 10% membrane-stained tumour cells were scored
1þ,2 þ or 3þ in Table 2. However, the percentage positive
tumour cells in all primary tumours and in all metastases were
actually in the range 50–100%. Therefore, all cutoff levels below
50% give the same result as reported in Table 2.
The intensity in staining in the primary tumours was, in most
cases, either strong (n¼23) or there was no staining at all (n¼13).
There were not so many cases with intermediate staining intensity,
faint staining (n¼8) and moderate staining (n¼3). This pattern
was similar in the lymph node metastases, which had strong
staining in 22 cases, moderate staining in four cases, faint staining
in two cases and no staining in 19 cases.
The major results from the HER2-score analyses are sum-
marised in Table 3. It is clear that in the majority of cases, there
were no changes between the primary tumours and the
corresponding lymph node metastases with respect to HER2
overexpression. Examples of staining patterns for a primary
tumour and the corresponding metastasis (which both were scored
as 3þ) are shown in Figure 1.
The literature was reviewed for recently published studies on
HER2 expression in primary breast tumours and corresponding
metastases (see Table 4). Only studies from the last 4 years and in
which HercepTest, or a similar immunohistochemical analysis, was
applied were included. It is concluded that breast cancer lymph
node metastases generally overexpress HER2 in a manner similar
to the corresponding primary tumours. In two studies (Vincent-
Salomon et al, 2002; Gancberg et al, 2002), distant metastases were
also analysed, and the conclusion was that these also express HER2
as the primary tumours. These conclusions are also supported by
previously published FISH studies (e.g. Thor, 2001; Xu et al, 2002).
The studies referred to in Table 4 also showed that the similar
scorings between the primary tumours and the corresponding
metastases were not due to random changes so that a number of
HER2 positive primary tumours that converted to HER2 negative
metastases were balanced by a similar number of conversions in
the other direction. Changes in HER2 expression actually seemed
to be extremely rare, although a few cases were reported, and the
Table 4 Recent examples from the literature on HER2 expression in primary tumours and the corresponding metastases
Report
Percentage IHC overexpression
in primary tumours
Percentage IHC overexpression
in metastases Comments
Masood and Bui (2000) 32% (n¼56) 32% (n¼56) 2+ or 3+ HercepTest
Shimizu et al (2000) 38% (n¼21) 38% (n¼21) +/  scale not HercepTest
Simon et al (2001) 24.8% (n¼125) 21.6% (n¼125) 2+ or 3+ HercepTest and/or positive FISH
Tanner et al (2001) 28% (n¼46) 28% (n¼46) 0–3+ scale but not HercepTest
Gancberg et al (2002) 29% (n¼100) 27% (n¼100)
a 2+ or 3+ HercepTest
Vincent-Salomon et al (2002) 25% (n¼44) 20.5% (n¼44)
b +/  scale not HercepTest
Tsutsui et al (2002) 25% (n¼76) 25% (n¼76) 0, +, ++ scale not HercepTest
This article 55% (n¼47) 55% (n¼47) 2+ or 3+ HercepTest
aMainly distant metastases.
bLiver and lung metastases. Lymph node metastases were analysed in all cases, except in the studies by Vincent-Salomon et al (2002) and Gancberg
et al (2002), where distant metastases were analysed
Table 2 HER2-scores for the analysed primary tumours and the
corresponding lymph node metastases (n¼47)
Lymph node metastases HER2-scores
Primary tumour
HER2-scores 0 1+ 2+ 3+
01 3 0 0 0
1+ 6 2 0 0
2+ 0 0 3 0
3 + 00 12 2
Table 3 Major results from the HER2-scores analyses (n¼47)
HER2-scores characteristics Fraction Percentage
Primary tumours with 3+ 23/47 49
Primary tumours with 2+ or 3+ 26/47 55
Lymph node metastases with 3+ 22/47 47
Lymph node metastases with 2+ or 3+ 26/47 55
Unchanged HER2-scores in lymph node metastases vs
the primary tumour
40/47 85
Changed HER2-scores in lymph node metastases vs the
primary tumour
7/47 15
Patients who had 0 or 1+ in primary tumours and
changed to 2+ or 3+ in lymph node metastases
0/47 0
Patients who had 2+ or 3+ in primary tumours and
changed to 0 or 1+ in lymph node metastases
0/47 0
Figure 1 Typical immunohistochemical HER2-stainings. A section from a
primary breast tumour (A) and a section of a lymph node metastasis (B)
from the same patient are shown. Both cases were scored 3þ.
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metastases are compared to the corresponding primary tumours.
It is noted that the percentage HER2 positive primary tumours
and metastases were higher in the present study than in the
previously published studies (Table 4). This is difficult to explain
since the selections of patient materials were, as far as we know,
random in all studies. However, it is possible that the tumours
included in our study were, on the average, of more aggressive type
than in the other studies. This is not possible for us to judge in
detail since we do not have detailed gradings for the different
studies (e.g. Elston scores). Our tumours were rather extensive
since it is seen from Table 1 that 37 tumours were classified as
pT2–pT4 while only 10 were classified as pT1. The aggressive
nature of our tumours also stems from the fact that all samples
were drawn from patients with subsequent distant metastases. This
probably gives a selection for high HER2-expressing tumours. For
example, in one study it has been reported that 60% of the studied
breast cancer bone marrow metastases were HER2 positive (Braun
et al, 2001). However, the aim of our study was to compare HER2
expression in primary tumours in relation to the corresponding
metastases and for that the considered data are hopefully good
enough in all the studies.
DISCUSSION
The results in the present study and in seven recently published
similar studies clearly showed that breast cancer metastases
generally overexpress HER2 in a manner similar to the corre-
sponding primary tumours. This stability in HER2 expression
seems surprising in the light of the genomic instability that
characterises most malignant tumours, including breast cancers.
Tumours are formed via multistep carcinogenesis (Bertram, 2000;
Onyango, 2002) involving defect onco-, supressor-, cell cycle- and
apoptosis-regulating genes. HER2 overexpression can be regarded
as overexpression of an oncogene product and erbB2 gene
amplification as an oncogene amplification. It is likely that
HER2 overexpression is, at least for some tumours, one of the
steps in the multistep process towards malignancy and that loss or
a decrease in HER2 expression therefore might decrease their
growth potential. Tumour cells that lose or downregulate HER2
will then be outgrown in an expanding tumour cell population.
They can possibly also be directed towards apoptosis since it has
been indicated that changes in HER2 expression can, at least in
combination with therapy, modify the route to apoptosis
(O’Rourke et al, 1998; Yarden and Sliwkowski, 2001).
The arguments given above about the lack of influence of
genomic instability on HER2 expression are also of interest when
HER2 targeted therapy is considered. It could be expected that an
efficient therapy based on targeting of HER2 would tend to induce
a selection for cells with low or no HER2 expression. However, as
discussed above, such cells might have a decreased growth
potential and, during therapy, even be triggered to apoptosis.
Thus, it is possible that HER2 is a suitable target also if treatment
induced selection is considered.
The observed stability in HER2 expression is also supported by
older studies on breast cancer (e.g. Niehans et al, 1993) and also by
studies on other tumours such as ovarian cancer (Tewari et al,
2000), cutaneous squamous carcinomas (Ahmed et al, 1997) and
urinary bladder carcinomas (Wester et al, 2002). However, besides
breast cancer no other tumour type has, with respect to this aspect,
been extensively analysed by so many research groups, and the
conclusions for the other tumour types must so far be considered
preliminary.
As mentioned in the Introduction, the treatment of disseminated
breast cancer needs improvement and it is necessary to consider
new therapy methods. Less than half of the patients with high
HER2 expression respond to Trastuzumab treatment (Cobleigh
et al, 1999; Slamon et al, 2001; McKeage and Perry, 2002). The
reason for failure is not known, but it has been shown that high
insulin-like growth factor-I receptor (IGF-I-R) signalling can
counteract the effects of Trastuzumab (Lu et al, 2001, 2004).
Another explanation might be heterogeneity of expression of HER2
between primary and metastatic tumour cells. The latter is,
however, an unlikely explanation considering the results sum-
marised in Table 4.
Targeting against HER2 not only with Trastuzumab but possibly
also with radiolabelled Trastuzumab could be an improvement.
Radionuclide therapy is a promising modality for treatment of
tumours of haematopoietic origin, while the success for treatment
of solid tumours has so far been limited (Carlsson et al, 2003).
However, the promising therapeutic results for haematological
tumours give hope that radionuclide therapy will have a break-
through also for treatment of disseminated cells from solid
tumours. Furthermore, resistance induction has so far not
been associated with radiation treatment. Antibody or anti-
body fragment-mediated targeting of toxins might be another
possibility.
New knowledge is continuously emerging with respect to
receptor targeting since pharmacokinetics and cellular processing
of different types of targeting agent are increasing and the research
dealing with molecular design of targeting agents is rapidly
expanding. The development of peptides and small proteins with
specificity against tumour cells is one strategy (Heppeler et al,
2000; Kwekkeboom et al, 2000; Park et al, 2000). The area of
antibody engineering is also rapidly developing and various forms
of antibody fragments are being developed such as minimal
recognising units, single-chain fragments (scFv) and dimeric scFv
(Adams et al, 2001; Goldenberg, 2003). Liposomes containing toxic
substances and conjugated with targeting agents (Park, 2002; Bohl
Kullberg et al, 2002) might be of special interest for killing of
disseminated tumour cells in the systemic circulation. Thus, there
are several possibilities for new and complementary strategies
when targeting of disseminated HER2 expressing breast cancer
cells are considered.
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